Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tyra Biosciences, Inc. (Nasdaq: TYRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing precision medicines targeting FGFR biology through its in-house SNÅP platform. Its SEC filings give investors structured insight into how the company reports its financial condition, pipeline progress and material events related to its FGFR-focused programs.
Among the key documents, Form 8-K current reports are used by Tyra to announce material events such as quarterly financial results and significant clinical milestones. For example, recent 8-K filings reference press releases reporting second and third quarter financial results and an 8-K dated June 30, 2025 describing the first patient dosed in the SURF302 Phase 2 study of TYRA-300 (dabogratinib) in intermediate risk non-muscle invasive bladder cancer. These filings often incorporate press releases by reference, linking financial metrics with updates on studies like SURF302, BEACH301, SURF301, SURF201 and SURF431.
Investors can also use Tyra’s periodic reports (such as the annual report on Form 10-K and subsequent filings referenced in forward-looking statement sections) to understand risk factors, research and development priorities, and the status of clinical-stage candidates including dabogratinib, TYRA-200 and TYRA-430. The company’s filings discuss topics such as trial design, anticipated data readouts, dependence on third parties, regulatory interactions and intellectual property considerations.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain complex sections, highlight key disclosures and point out items of interest such as clinical trial milestones, cash runway commentary and forward-looking statements tied to the SNÅP platform and FGFR-targeted pipeline. Users can quickly review newly posted 8-Ks, 10-Ks and other forms, and connect them to Tyra’s broader narrative in precision oncology and genetically defined skeletal dysplasias.
Tyra Biosciences, Inc. reported that Chief Medical Officer Douglas J. Warner received new equity awards as part of his compensation. He was granted 25,000 restricted stock units (RSUs), each representing one share of common stock, with one quarter vesting on each of the first four anniversaries of May 5, 2026, subject to his continuous service. He also received a stock option for 85,000 shares of common stock at an exercise price of $33.93 per share, vesting in equal monthly installments over 48 months following May 5, 2026, also conditioned on continued service. These are grants and not open‑market purchases or sales.
Tyra Biosciences, Inc. granted Chief Financial Officer Alan Fuhrman new equity awards on May 5, 2026. He received 20,000 restricted stock units, which vest in four equal annual installments starting on May 5, 2027, each RSU representing one share of common stock. He was also granted options on 67,000 shares of common stock at an exercise price of $33.93 per share, vesting monthly over four years and expiring on May 4, 2036. Following these awards, he directly owns 36,164 shares of common stock, including RSUs.
Tyra Biosciences President and CEO Harris Todd received new equity awards that increase his long-term stake in the company. He was granted 79,000 restricted stock units on May 5, 2026, bringing his direct common stock holdings to 1,437,631 shares after the award.
He also received a stock option for 265,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036. The RSUs vest in four equal annual installments starting on the first anniversary of May 5, 2026, while the option vests monthly over 48 months from the same date, in each case subject to his continuous service.
Tyra Biosciences Chief Operating Officer Ashar Bhavesh received new equity awards in the form of restricted stock units and stock options. On May 5, 2026, Bhavesh was granted 15,013 RSUs, each representing a right to receive one share of common stock, and 50,295 stock options with an exercise price of $33.93 per share.
According to the vesting terms, one quarter of the RSUs vests on each of the first four anniversaries of May 5, 2026, subject to continued service. For the options, 25% of the shares vest on May 5, 2027 and the remainder vests in equal monthly installments over the following three years, with the options expiring on May 4, 2036.
Tyra Biosciences, Inc. reported that Vice President, Finance (PAO) Yuliya Rueb received equity compensation on May 5, 2026. She was granted 8,333 restricted stock units (RSUs), each representing one share of common stock, with 1/4 of the RSUs vesting on each of the first four anniversaries of May 5, 2026, subject to continued service. Following this grant, she holds 43,354 shares of common stock directly, including RSUs. She was also granted a stock option for 28,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036, with 1/48 of the option shares vesting monthly after May 5, 2026, as long as she remains in service.
Canaan-affiliated investors amend Schedule 13G/A to report beneficial ownership in Tyra Biosciences. The filing states Canaan XI L.P. and its general partner Canaan Partners XI LLC each have sole voting and dispositive power over 750,000 shares of Tyra common stock, representing 1.4% of the class. The percent is calculated using 53,867,115 shares outstanding as of February 25, 2026. The amendment also states that Canaan 2020+ Co-Investment L.P. - Series 7 and its GP no longer beneficially own any shares as of March 31, 2026.
Tyra Biosciences director Habib J. Dable received a grant of stock options covering 44,400 shares of common stock at an exercise price of $35.12 per share. The options expire on April 15, 2036 and vest monthly in 36 equal installments starting after April 16, 2026, contingent on continued service.
Tyra Biosciences, Inc. director Dable Habib J filed an initial Form 3 reporting his ownership position in the company. The filing states that no securities are beneficially owned, meaning he reports holding zero Tyra Biosciences shares at this time.
Tyra Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 Annual Meeting on May 28, 2026. Holders of Common Stock at the close of business on April 2, 2026, when 59,485,237 shares were outstanding, are entitled to vote.
Stockholders will vote on electing three Class II directors—Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More—for terms expiring at the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. The Board recommends voting in favor of all nominees and the auditor ratification.